drugset / Trial / NCT01402245

Targeting of Immune Response After Pneumococcal Vaccination

NCT01402245

Phase 4 Completed 42 enrolled Helsinki University Central Hospital
Non-randomizedParallel-groupOpen-labelPrevention

Summary

Pneumococcal polysaccharide vaccine does not confer protection against noninvasive pneumonia. The study aims to compare lymphocyte homing in pneumonia and in those receiving Pnc polysaccharide vaccine (PPV) or Pnc conjugate vaccine (PCV)

Timeline

Start
2005-01
Primary completion
2010-06
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pneumovax 23 Vaccine 0.5 ml Intramuscular
Comparator Prevnar 13 Vaccine 0.5 ml Intramuscular